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In medicine, it is encouraging when research yields results consistent with our under-
standing of the operative mechanisms, especially when there is a direct potential impact 
on clinical practice. Adverse left ventricular (LV) remodeling is a complex maladaptive 
process involving structural, hemodynamic, histopathological, and genetics changes.1 
The process may be multifactorial and is frequently encountered in patients after loss 
of myocardium (myocardial infarction), volume overload (valvular insufficiency), or 
pressure overload (hypertension). It involves both LV hypertrophy and dilation, and 
is initially an adaptive response that serves to maintain stroke volume. If persistent 
and progressive, the process becomes maladaptive and leads to further deterioration 
of LV function, LV dilation, and eventually the typical symptoms of heart failure.
It is evident that substantial prolongation of the QRS complex, especially with a 
left bundle branch block (LBBB) pattern, results in a delayed and dyssynchronous 
LV contraction.2 This dyssynchrony may be a major contributor that can both initiate 
and aggravate the process of adverse remodeling. In patients with symptomatic heart 
failure, systolic dysfunction, and QRS prolongation, cardiac resynchronization therapy 
(CRT) has been shown to be highly efficacious in reducing morbidity and prolonging 
survival.3 There is concordance between the reductions in LV volumes, the best indices 
of LV remodeling, and improvement in clinical outcomes.4
Acute and chronic right ventricular (RV) pacing results in substantial widening of 
the QRS complex and induces both inter- and intra-ventricular dyssynchrony (iatrogenic 
LBBB).5 Improvements in measures of dyssynchrony following CRT in patients with 
heart failure and previous RV pacing have been demonstrated.6
The PACE trial, a prospective double-blind, multicenter study, was designed to 
compare apical RV pacing with CRT in patients with bradycardia and a preserved 
LV ejection fraction (EF). A total of 177 patients with a conventional indication 
for a pacemaker and preserved LV function (EF >45%), were following successful 
implantation of a CRT device, randomized and programmed to either RV pacing or 
CRT pacing. The trial evaluated LV function and measurements of remodeling over 
12 months at a blinded core laboratory using three-dimensional echocardiography. 
The results published in the New England Journal of Medicine in 2010 demonstrated 
significant and substantial reductions in LVEF and increases in end-systolic LV vol-
umes in the RV pacing group during the 1- year follow up. Evidence of deterioration 
in LV function was not observed in the group with CRT pacing. Adverse changes 
in patients paced only in the RV included: A significant increase of 6.3 milliliter on 
average in the size of the LV at the end contraction and a decrease of 6.8 percent in 
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the EF, or the amount of available blood pumped from the 
LV. These results show bi-ventricular pacing may be superior 
to pacing only in the RV to preserve the heart´s normal LV 
size and pumping ability for these pacemaker patients.7 The 
reported findings are consistent with previous reports, apart 
from the PREVENT-HF trial which did not demonstrate LV 
function differences over 1 year in a similar population with 
preserved EF.8
The PACE trial provides trial evidence that should be 
taken into consideration by physicians responsible for the 
management of patients with conventional pacing indica-
tion. However, there remain several important unanswered 
questions.
Right ventricular pacing in patients with sinus node dys-
function without atrioventricular block is not required and may 
have resulted in avoidable reverse remodeling in these patients. 
This is perhaps the most important methodological and ethical 
criticism of this trial. The lack of between-group difference on 
6-minute walk distance or the quality of life tool may appear 
surprising at first. However, these were not patients with heart 
failure or reduced EF. As we know, CRT is associated with 
improvements in symptoms, functional capacity, and clinical 
outcomes in symptomatic patients with systolic dysfunction.
The PACE trial was underpowered for analysis of clinical 
events. The sample was small and the follow up was short, 
especially for asymptomatic patients with preserved EF.
There is of course some non-trivial, added morbidity as-
sociated with CRT implantation as compared with RV pacing, 
especially with inexperienced operators. What amount of 
benefit would justify the modest increased risk at implantation 
as well as the increase cost of a device with shorter longevity.
Obviously, much depends on the pacing indication. Pa-
tients with infrequent episodes of bradycardia requiring a back 
up pacemaker would not be candidates. However, if there is 
AV block and expectation of pacemaker dependency, a de-
vice that results in chronic RV pacing will be likely to put the 
patient at risk for adverse remodeling and it may begin soon 
after the implantation and progress. However, isolated sinus 
node dysfunction without AV block may not required an RV 
lead, and the PACE trial results do not support implantation 
of a CRT in this population. As with all therapies, the patient’s 
biological age, functional status, and extent of co-morbidity 
will enter into the management decision.
Future clinical research must address the major unan-
swered questions. How should we identify the target popula-
tion at greatest risk for adverse remodeling following RV 
pacing and therefore likely to benefit from a CRT device. Will 
CRT in patients with bradycardia and preserved systolic func-
tion translate into prevention of meaningful adverse endpoints 
such as hospitalization for heart failure. If so, it becomes a good 
investment. Benjamin Franklin put it well: An ounce of preven-
tion is worth a pound of cure. In this case, it is about 2 ounces.
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